Elicera Therapeutics AB (FRA:8E8) Quality Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:8E8 Elicera Therapeutics AB FRA:8E8
25 GF Score
Price €0.19
! 1 Warning Sign
View Full Analysis

What is Elicera Therapeutics AB Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Elicera Therapeutics AB Quality Rank Related Terms

FRA:8E8
25GF Score
Elicera Therapeutics AB FRA:8E8
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Elicera Therapeutics AB Business Description

Other Exchanges ELIC:Sweden
Address Massans gata 10, World Trade Center Goteborg, 7th Floor, Goteborg, SWE, 412 51
Elicera Therapeutics AB is a Sweden-based clinical-stage immuno-oncology company developing cell and gene therapies for immune-based cancer treatments. Its product portfolio consists of four drug candidates, including two in the field of oncolytic viruses (ELC-100 and ELC-201) and two in the field of CAR T-cell treatments (ELC-301 and ELC-401), in addition to the universal CAR T-cell technology platform, iTANK (ELC-001). The Company is running four internal immunotherapy development projects, comprising two CAR T-cell programs and two oncolytic virus programs.
25GF Score

Get the complete analysis for FRA:8E8

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.19
Price